FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3103380324> ?p ?o ?g. }

• W3103380324 abstract "Background Personalized cancer immunotherapies can generate potent antitumor responses yet finding the right targets remains challenging. The ATLAS TM platform employs ex vivo functional screening of tumor mutations using autologous cells to identify patient-specific neoantigens. Stimulatory neoantigens are identified by upregulation of inflammatory cytokine secretion and can be employed in vaccines or cell therapies. Conversely, ATLAS also identifies inhibitory neoantigens (termed Inhibigens) that lead to cytokine downregulation, and in murine models accelerate tumor growth and abrogate the efficacy of otherwise-protective vaccines. Here we further explore Inhibigen mechanism of action in humans and mice including whether checkpoint inhibition (CPI) can ameliorate Inhibigen-accelerated tumor growth. Methods Human and mouse ATLAS screens were performed as previously described. 1 ATLAS-identified stimulatory or Inhibigen peptide vaccines were evaluated in a therapeutic B16F10 melanoma tumor model ± CPI. Immune responses were measured using ELISPOT, flow cytometry, and immunohistochemistry (IHC). Results In the GEN-009 personalized neoantigen vaccine trial ( NCT03633110 ), Inhibigens were observed in 92% of patients (N=39). Of total mutations screened, 16% (1.8 - 47.5%) were classified as Inhibigens, which were found more often in the CD4 + (mean 10.3%; 0.5 - 42%) versus CD8 + T cell subset (mean 6.1%; 1.2–23%). No relationship between Inhibigen-specific responses and tumor type or mutational burden were observed. To study the functional effects of Inhibigen vaccination in vivo, a B16F10 mouse melanoma model was employed. Inclusion of Inhibigens in an otherwise protective vaccine abrogated efficacy and correlated with decreased T cell responses to vaccine antigens as well as a global depression of T cell cytokine secretion. Early experiments suggest that these decreases are not due to MHC competition. In addition, administration of a therapeutic vaccine containing an Inhibigen led to reduced tumor infiltration of CD8 + T cells and myeloid populations. A corresponding increase of classical Tregs in the tumor or periphery was not observed. Surprisingly, preliminary data show combination therapy with anti-CTLA4 partially ameliorated Inhibigen-accelerated tumor growth but anti-PD1 provided no additional benefit. Conclusions The nearly ubiquitous presence of Inhibigens in human cancer patients and the demonstrated pro-tumor effects in mice suggest that ATLAS-identified Inhibigens must be considered and omitted in the design of cancer immunotherapies. Furthermore, in mice, CPI co-administration has a modest (anti-CTLA4) or no (anti-PD1) effect on Inhibigen-accelerated tumor growth suggesting that Inhibigen profiling could guide CPI selection or predict clinical outcome. These data confirm the benefits of the ATLAS platform for neoantigen and Inhibigen identification. Ethics Approval All animal studies were undertaken in conformity with the Cambridge, MA City Ordinance 1086 of the city’s Municipal Code and in accordance with the policies and protocols approved by Genocea’s Institutional Animal Care and Use Committee (IACUC). Reference Nogueira C, Kaufmann JK, Lam H, Flechtner JB. Improving cancer immunotherapies through empirical neoantigen selection. Trends in Cancer 2018 Feb;4(2):97–100" @default.
• W3103380324 created "2020-11-23" @default.
• W3103380324 creator A5002478532 @default.
• W3103380324 creator A5016380391 @default.
• W3103380324 creator A5020122874 @default.
• W3103380324 creator A5026569672 @default.
• W3103380324 creator A5029038858 @default.
• W3103380324 creator A5032019897 @default.
• W3103380324 creator A5036783909 @default.
• W3103380324 creator A5053765475 @default.
• W3103380324 creator A5058042069 @default.
• W3103380324 creator A5067072586 @default.
• W3103380324 creator A5069648611 @default.
• W3103380324 creator A5072318387 @default.
• W3103380324 creator A5077557341 @default.
• W3103380324 date "2020-11-01" @default.
• W3103380324 modified "2023-09-27" @default.
• W3103380324 title "526 InhibigenTM-specific responses suppress anti-tumor immunity and promote tumor growth" @default.
• W3103380324 cites W2781772206 @default.
• W3103380324 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0526" @default.
• W3103380324 hasPublicationYear "2020" @default.
• W3103380324 type Work @default.
• W3103380324 sameAs 3103380324 @default.
• W3103380324 citedByCount "0" @default.
• W3103380324 crossrefType "journal-article" @default.
• W3103380324 hasAuthorship W3103380324A5002478532 @default.
• W3103380324 hasAuthorship W3103380324A5016380391 @default.
• W3103380324 hasAuthorship W3103380324A5020122874 @default.
• W3103380324 hasAuthorship W3103380324A5026569672 @default.
• W3103380324 hasAuthorship W3103380324A5029038858 @default.
• W3103380324 hasAuthorship W3103380324A5032019897 @default.
• W3103380324 hasAuthorship W3103380324A5036783909 @default.
• W3103380324 hasAuthorship W3103380324A5053765475 @default.
• W3103380324 hasAuthorship W3103380324A5058042069 @default.
• W3103380324 hasAuthorship W3103380324A5067072586 @default.
• W3103380324 hasAuthorship W3103380324A5069648611 @default.
• W3103380324 hasAuthorship W3103380324A5072318387 @default.
• W3103380324 hasAuthorship W3103380324A5077557341 @default.
• W3103380324 hasConcept C147483822 @default.
• W3103380324 hasConcept C150903083 @default.
• W3103380324 hasConcept C167672396 @default.
• W3103380324 hasConcept C203014093 @default.
• W3103380324 hasConcept C207001950 @default.
• W3103380324 hasConcept C22070199 @default.
• W3103380324 hasConcept C26291073 @default.
• W3103380324 hasConcept C2776090121 @default.
• W3103380324 hasConcept C2776662205 @default.
• W3103380324 hasConcept C2777658100 @default.
• W3103380324 hasConcept C2777701055 @default.
• W3103380324 hasConcept C2778690821 @default.
• W3103380324 hasConcept C2779053233 @default.
• W3103380324 hasConcept C2780674031 @default.
• W3103380324 hasConcept C502942594 @default.
• W3103380324 hasConcept C71924100 @default.
• W3103380324 hasConcept C86803240 @default.
• W3103380324 hasConcept C8891405 @default.
• W3103380324 hasConceptScore W3103380324C147483822 @default.
• W3103380324 hasConceptScore W3103380324C150903083 @default.
• W3103380324 hasConceptScore W3103380324C167672396 @default.
• W3103380324 hasConceptScore W3103380324C203014093 @default.
• W3103380324 hasConceptScore W3103380324C207001950 @default.
• W3103380324 hasConceptScore W3103380324C22070199 @default.
• W3103380324 hasConceptScore W3103380324C26291073 @default.
• W3103380324 hasConceptScore W3103380324C2776090121 @default.
• W3103380324 hasConceptScore W3103380324C2776662205 @default.
• W3103380324 hasConceptScore W3103380324C2777658100 @default.
• W3103380324 hasConceptScore W3103380324C2777701055 @default.
• W3103380324 hasConceptScore W3103380324C2778690821 @default.
• W3103380324 hasConceptScore W3103380324C2779053233 @default.
• W3103380324 hasConceptScore W3103380324C2780674031 @default.
• W3103380324 hasConceptScore W3103380324C502942594 @default.
• W3103380324 hasConceptScore W3103380324C71924100 @default.
• W3103380324 hasConceptScore W3103380324C86803240 @default.
• W3103380324 hasConceptScore W3103380324C8891405 @default.
• W3103380324 hasLocation W31033803241 @default.
• W3103380324 hasOpenAccess W3103380324 @default.
• W3103380324 hasPrimaryLocation W31033803241 @default.
• W3103380324 hasRelatedWork W16473764 @default.
• W3103380324 hasRelatedWork W19818330 @default.
• W3103380324 hasRelatedWork W20203410 @default.
• W3103380324 hasRelatedWork W2151330 @default.
• W3103380324 hasRelatedWork W2773312 @default.
• W3103380324 hasRelatedWork W334662 @default.
• W3103380324 hasRelatedWork W4041773 @default.
• W3103380324 hasRelatedWork W6417289 @default.
• W3103380324 hasRelatedWork W8453341 @default.
• W3103380324 hasRelatedWork W9749177 @default.
• W3103380324 isParatext "false" @default.
• W3103380324 isRetracted "false" @default.
• W3103380324 magId "3103380324" @default.
• W3103380324 workType "article" @default.